| 2017-05-18 09:04:08 | Endologix downgraded to Perform from Outperform at OppenheimerOppenheimer analyst Steven Lichtman downgraded Endologix to Perform and lowered his price target for the shares to $5.50 from $10. The downgrade follows the company's announcement that it willseek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study. BTIG and Stifel this morning also downgraded Endologix. | |
|---|---|---|
| ||
| ||
| | |
| , |
| |
| , |
| |
|
| | |
| , … |
| |
| , |
| |
| | |
| , … |
| |
| | |
| | |
| ||
| | |
| |
| , |
| |
|---|---|---|
| ||
| ||
| ||
| |
| ||
| ||
| ||
| | |
|